Pure Global
NCT06406686

Ablation Index in Standard vs. High Power Radiofrequency Ablation for Typical Atrial Flutter: A Randomized Study (AITAF)

University of Calgary·ClinicalTrials.gov·procedureNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Atrial Flutter,Atrial Flutter Typical,Cavotricuspid Isthmus Dependent Macroreentry Tachycardia
Drug/Device/Intervention
Ablation of the Cavo-tricuspid isthmus for typical Atrial Flutter
Study type
Interventional
Intervention type
procedure
Sponsor & location
Primary sponsor
University of Calgary
Location
Calgary, Canada
Timeline & enrollment
Phase
N/A
Start date
Jun 03, 2024
End date
Jun 03, 2025
Enrollment
50 participants
Primary outcome

RF time to durable CTI block

Summary

A randomized controlled trial will be conducted to evaluate the efficacy of Ablation
 Index-guided high power - short duration (HPSD) ablation compared to conventional power
 settings in Cavotricuspid Isthmus (CTI) dependent atrial flutter. Participants will be
 randomized to receive either AI-guided HPSD ablation at 50 Watts or conventional power
 settings at 30 Watts. Both arms will use the Carto 3D mapping system and the QDOT MICRO
 ablation catheter (Biosense Webster). An anatomically contiguous line will be created with
 6mm inter-lesion distance. After a standardized wait time of 30 minutes, ablation success
 will be assessed. The primary outcome is total radiofrequency ablation time. Secondary
 outcomes include procedural time, fluoroscopy time, safety outcomes, and 3-month freedom from
 recurrence. It is our expectation that HPSD will result in a shorter primary outcome.

ICD-10 classifications
Atypical atrial flutterTypical atrial flutterAtrial fibrillation and atrial flutter, unspecifiedAtrial fibrillation and flutterTachycardia, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06406686
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06406686 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Calgary and is currently Not yet recruiting. The study focuses on Atrial Flutter,Atrial Flutter Typical,Cavotricuspid Isthmus Dependent Macroreentry Tachycardia. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.